Compare BioNTech SE - ADR (BNTX) vs PubMatic Inc (PUBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs PubMatic Inc — how do they compare? BioNTech SE - ADR trades at $92.23 (market cap $23.31B), while PubMatic Inc trades at $17.52 (market cap $808.97M). The key difference: BioNTech SE - ADR is far larger — about 28.8× PubMatic Inc's market cap, and PubMatic Inc is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | PUBM | |
|---|---|---|
Market Cap | $23.31B | $808.97M |
Sector | Health | Technology |
52-Week High | $119.34 | $17.78 |
52-Week Low | $83.89 | $6.28 |
Enterprise Value | $6.60B | $712.10M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
PUBM's stock surged 31.9% to $17.78, reflecting strong investor optimism following a Q2 2026 earnings beat with 10.5% revenue growth and improved profitability in mobile app and CTV segments. Technical indicators show a bullish trend with support at $17 and resistance at $18, though RSI levels suggest overbought conditions. The company maintains a robust balance sheet with $120M in cash and positive operating cash flow of $81.06M in 2025, despite a net loss of -$14.46M. Recent leadership changes, including the appointment of a new Global Chief Revenue Officer, aim to accelerate growth amid AI-driven advertising transformations.
The outlook for PUBM is cautiously optimistic, with a consensus price target of $21.50 offering 21% upside potential. Key opportunities include double-digit revenue growth in high-margin segments and AI product adoption, but risks persist from competitive pressures, profitability challenges, and reliance on digital advertising cyclicality. Investors should weigh the strong analyst buy ratings against elevated valuation multiples and execution risks in a dynamic market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
